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Abstract
Background: Schistosomiasis is endemic in 54 countries, but has one of the lowest coverages by mass drug
administration of all helminth diseases. However, with increasing drug availability through donation, the World
Health Organisation has set a goal of increasing coverage to 75 % of at-risk children in endemic countries and
elimination in some regions. In this paper, we assess the impact on schistosomiasis of the WHO goals in terms of
control and elimination.
Methods: We use an age-structured deterministic model of schistosome transmission in a human community and
the effect of mass drug administration. The model is fitted to baseline data from a longitudinal re-infection study in
Kenya and validated against the subsequent re-infection data. We examine the impact on host worm burden of the
current treatment trend, extrapolated to meet the WHO goals, and its sensitivity to uncertainty in important
parameters. We assess the feasibility of achieving elimination.
Results: Model results show that the current treatment trend, extrapolated to the WHO goals, is able to greatly
reduce host worm burdens. If coverage is continued at the same level beyond 2020, elimination is possible for low
to moderate transmission settings, where transmission intensity is defined by the basic reproduction number, R0.
Low levels of adult coverage have a significant impact on worm burden in all settings. Model validation against the
re-infection survey demonstrates that the age-structured model is able to match post-treatment data well in terms
of egg output, but that some details of re-infection among school children and young adults are not currently well
represented.
Conclusions: Our work suggests that the current WHO treatment goals should be successful in bringing about a
major reduction in schistosome infection in treated communities. If continued over a 15 year period, they are likely
to result in elimination, at least in areas with lower transmission.
Background
The third progress report of the London Declaration re-
cords that schistosomiasis remains red in the progress
score card chart (recently developed by Uniting to Com-
bat NTDs) as it has the lowest coverage of all helminth
diseases treatable by mass drug administration (MDA) at
14.4 % in 2012 and 15.6 % in 2013 [1]. In addition, new
mapping of schistosomiasis in affected countries is in-
creasing the number of identified districts with endemic
infection. Only twenty-six countries (50 %) of 52 en-
demic countries reported MDA in 2013 [1]. The report
argues that significant improvements could be made in
the coming years as drug supply of praziquantel is ex-
pected to increase and the launching of the new Global
Schistosomiasis Alliance will increase collaboration
within this disease community to help countries scale up
MDA of children and adults [2].
Global treatment numbers for schistosomiasis have
slightly improved in recent years. In 2013, 47.3 million
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people were treated with praziquantel, while the com-
parative figure was 42 million in 2012. However, dona-
tions of praziquantel are increasing significantly. In
2014, pharmaceutical donor Merck increased its contri-
bution to nearly 75 million tablets, and of 41 African
countries requiring treatment, 36 (88 %) were reached.
Merck has increased its donation in 2015 to 100 million
tablets. For 2016, Merck has committed to increasing its
donation of praziquantel up to 250 million tablets,
equivalent to 100 million treatments. As reported in the
third progress report, DFID, USAID, the World Bank,
and World Vision also purchased over 100 million of
praziquantel tablets in 2015 [1].
The targets set by the World Health Organization
(WHO) at the 2015 World Health Assembly (WHA) for
schistosomiasis control are elimination as a public health
problem, by 2015 in the Eastern Mediterranean, Carib-
bean. Indonesia and the Mekong River Basin, and by
2020 regionally in the Americas and Western Pacific and
nationally in selected African countries (Fig. 1). To
achieve these ambitious targets WHO aims that 75 % of
school-aged children (SAC) in need of preventive treat-
ment will be regularly treated in 100 % of endemic coun-
tries by 2020 [3]. For these targets elimination is not
defined clearly, nor is the frequency of treatment
required.
In this paper, we address what might be required to
eliminate transmission for Schistosoma mansoni using
annual MDA coverage in pre-SAC, SAC and adults. We
also assess the impact on host worm burden of historic
coverage levels, projected forward to 75 % in SAC by
2020. Only in six of 31 reporting countries was the
target of reaching at least 75 % of school children
achieved [4].
To provide quantitative predictions of MDA impact
we employ deterministic age structured mathematical
models that incorporating sexual reproduction, aggre-
gated distributions of worm numbers per host (described
by the negative binomial distribution with aggregation
parameter k), density dependent egg production and
variable contact with, and production of, infective stages
to continue the life cycle, by different age groupings of
the host population, defined as pre-school aged children
(pre-SAC, 0–4 years of age), school aged children (SAC,
5 to 14 years of age), and adults (> 15 years of age). The
model template is described in Anderson & May [5] and
modifications to this structure to include variable expos-
ure to infection and production of eggs by host age
groupings are detailed in Truscott et al. [6].
Methods
Details of the mathematical model employed are de-
scribed in previous publications [6–8] and also in
Additional file 1. Most research on model development
for schistosome transmission is based on the pioneering
studies of Macdonald in the 1960s [9]. He was the first
Fig. 1 Distribution of schistosomiasis worldwide in 2013 as reported by the WHO [1]
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to point out that sexual reproduction in dioecious spe-
cies created a breakpoint in transmission (an unstable
equilibrium separating the two stable points of endemic
infection and parasite extinction) below which mating
frequency is insufficient to sustain transmission. More
recent modifications include the inclusion of negative bi-
nomial distributions of parasite number per host [10,
11]. Worm counts based on autopsy studies show clearly
that parasites are highly aggregated within the host
population where most hosts harbour few parasites and
a few harbour many [12]. These autopsy results are also
confirmed by plots of the prevalence of infection versus
mean epg counts which also show high degrees of aggre-
gation [13, 14].
Other important modifications in past work include
the demography of the human host population [15], the
impact of MDA [16–18], acquired immunity (dependent
on past exposure to infection) [10], spatial structure and
host gender [19], density dependence in egg production
[20], predisposition to heavy infection [13], stochastic in-
dividual based models [20] and the generation of para-
site aggregation through heterogeneity in exposure
amongst the host population [20, 21].
In this paper we employ a deterministic hybrid model
which assumes the parasite is dioecious and monogam-
ous, has density dependent egg production [20] and a
degree of parasite aggregation defined by the negative bi-
nomial probability distribution with a fixed value of the
aggregation parameter k. The details of the model can
be found in the supplementary information. The within-
host section of the model describes the evolution of the
worm burden in individuals as a function of age. It has
full age structure, but outputs are grouped into three
age groupings for pre-SAC (0–4 years of age), SAC (5–
14 years of age) and adults (>15 years of age), reflecting
the key age distinctions made within MDA programs.
We include variability in host exposure to infection and
contributions to egg production dependent on host age
group (described by a parameter βi which describes the
intensity of infectious contact of age group i with the in-
fectious material in the environment. Because of the
relative fast time scales of turnover in the larval stages
and snail intermediate host of schistosomes (see review
by Anderson & May [16]), relative to the long life ex-
pectancy of the adult worm in the human host, the de-
tails of the dynamics of the free living and snail based
stages of the parasite are collapsed into an equation for
infectious material in the environment.
The history of treatment coverage with praziquantel in
the SAC age group (5–14 years of age) and adults
combined as reported by WHO is as illustrated in Fig. 2
[4, 22]. We have partition the national coverage data to
give values for SAC and adults separately. Coverage of
SAC for the years after 2014 was constructed as a linear
trend from the last data time-point to an assumed level
of 75 % in 2020 and beyond. Adult coverage was con-
structed to remain in constant proportion to SAC cover-
age over the period 2014–20, reaching a plateau at about
27 %. In a recent review the mean egg reduction rate
(ERR) reported for a 40 mg dose of praziquantel was
95 % for S. japonicum, 94.1 % for S. haematobium, and
86.3 % for S. mansoni. The drug currently is not recom-
mended for use in pre-SAC [23].
Parameter assignments for the major population and
transmission processes were as defined in Table 1 based
on the extraction of values from epidemiological studies
of S mansoni in Kenya by Butterworth and colleagues
using a full cross sectional age - average intensity profile
[24–26]. Parameters were estimated using maximum
likelihood techniques applied to the mean epg age pro-
files. Parameters not well informed by this data were
taken from other studies in the literature as recorded in
Table 1. The age intensity profiles (based on mean epg
counts) pre- and post-treatment are recorded in Fig. 3. A
fit of the model to one set of data is recorded in Fig. 4.
The issue of whether or not the convex age intensity
curves recorded for the schistosomes are due to ac-
quired immunity or age related exposure remains uncer-
tain. The problem of observed epidemiological pattern
interpretation was first enunciated by Warren in 1973
who described the problem succinctly as one of differen-
tiating between ecology and immunology [27]. The con-
undrum in interpretation remains today, although there
is abundant clinical evidence of the mounting of strong
and specific immunological responses to schistosome in-
fections by the human host [28]. In our analyses of the
impact of MDA, we assume that the convex age inten-
sity profiles are generated by age dependent exposure.
Future work will assess the impact of weakening this as-
sumption to include the more realistic premise that both
ecology and immunology act as determinants.
Treatment coverage is assumed to be at random at
each round of MDA in each age group. This is unlikely
to be true in reality and a future publication will exam-
ine adherence issues within a stochastic framework. If
those not treated are predisposed to this state for social
or behavioural factors, the impact of MDA at 75 %
coverage will be less than predicted in the results dis-
cussed in this paper.
Host demographic details (age dependent death rates
and population pyramids) were taken from published
data on sub-Saharan countries with the profile in
Uganda chosen to represent a typical profile for sub-
Saharan Africa where S. mansoni is endemic [29].
Model validation
Validation of model predictions is essential and can be
performed in variety of ways. Qualitative comparisons of
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model prediction with observed pattern of reinfection
post mass treatment is one approach. Ideally, however,
quantitative comparisons of predicted outcome of the
impact of MDA require parameter estimation using data
from a defined population with little or no recent past
treatment and then the comparison of expected and ob-
served patterns of reinfection at subsequent rounds.
Given the age structured nature of the current model, a
detailed validation requires precise information on who
has been treated, at what age, how often and their repre-
sentation within the final reinfection survey. For schisto-
somes , worm loads are usually measured indirectly by
eggs per gram of faeces (epg) or per unit volume of
urine in the case of S haematobium. This measure is
known to be unreliable, typically underestimating the
true prevalence. Furthermore, in estimating intensity, it
has a high variance as recorded in repeated samples
from the same stool and in stools taken on consecutive
days [30]. New tools, such as quantitative PCR, offer
some hope for the future in providing precise scores for
prevalence, and perhaps even egg burdens in stools. A
further complication arises from density dependence in
egg production by female worms which can result in
higher per capita egg output post the initial round of
treatment during the early phases of reinfection.
Model validation has rarely been attempted for helminth
infections, but it is a central need for ongoing and future
epidemiological studies of MDA impact, if predictions on
coverage requirements to interrupt transmission are to
carry weight amongst public health policy makers. A
Fig. 2 National coverage in endemic regions as reported by the WHO. The age-specific (SAC and adults) coverages, were estimated from the
national figures by assuming that SAC account for 70 % of all those treated [4], and are 46 % of the current Population requiring PC (based on
PCT data bank [22]). The trends in SAC and adult coverage are represented by the orange and grey lines, respectively. Solid lines represent
reported figures and broken lines the project trends in coverage to reach 75 % coverage for SAC in 2020 and maintain the current ratio of SAC/
adult coverage. In model projections, coverage levels are assumed to be constant after 2020
Table 1 Parameter values used in the numerical evaluations of model predictions for S mansoni. The age intensity profile from the
cited sources based on faecal egg counts were used to derive estimate of R0 and βi using maximum likelihood methods. The age
groupings for the contact parameter βi are defined as the intervals between 0, 5, 10, 16 and 80 years
Parameter Value Source
Basic Reproductive number, R0 2.00 Fitted
Adult worm life expectancy 4 years [10]
Negative binomial clumping parameter, k 0.24 [34]
Density dependence fecundityparameter, ɣ 0.0006/female worm [34]
Beta, βi for intensity of age group i’s contact with infectious material 0.22,1.88,1,0.53 Fitted
Drug efficacy as a proportion of worms killed by praziquantel 0.86 [44]
Egg output per female worm 0.14 [45]
Source of age - mean intensity data - Ietune village, Machakos District, Kenya [26]
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previous attempt by French et al. (2010) used pre and post
treatment epg counts from a study of S mansoni in
Uganda recording reinfection over 3 years of follow up,
but validation was based on estimating parameter values
from the trends in reinfection [17]. Ideally, it should be
done by estimating these parameters first, and then pre-
dicting reinfection pattern to compare with observed out-
comes given data on treatment coverage.
We report a validation exercise using a reinfection
study of S mansoni recording prevalence and mean epgs
in a set of villages in Kenya that had not previously been
treated prior to the initiation of mass drug administra-
tion [26]. We also examine the sensitivity of model pre-
dictions of the impact of achieving 75 % coverage in
SAC to changes of R0, to different values of the contact
parameter βi and to the level of drug coverage especially
in adults.
Results
We present the results of the numerical evaluations of
model behaviour under the coverage trends shown in
Fig. 2 and the parameters described in Table 1. Figure 5
displays a histogram recording the initial mean female
worm burden in 2001 in pre-SAC (<5 years of age - no
treatment coverage), SAC (5–15) and adults (15+ years
old), and the respective worm burdens at year 2020
resulting from the treatment coverage trend shown in
Fig. 2. Note that the clear peaked profile shown in Fig. 4
Fig. 3 Age mean intensity (epg) profiles for S.mansoni in two Kenyan villages from Fulford et al. (1995) pre (solid line) and post (dashed line)
MDA with praziquantel. Note the large impact that MDA has in these settings. The village in Graph B was used in parameter estimation
employing likelihood methods to fit the model to the observed mean epg counts
Fig. 4 Maximum likelihood fit of the deterministic model to age cross sectional data of the mean intensity of infection (epg counts) from Iietune
village in Kenya (Fulford et al., 1995) as plotted in Fig. 3. The solid line is the best fit and the crosses are the raw data. The estimated parameter
values are recorded in Table 1
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is lost when averaging across pre-SAC, SAC and adult
age categories as a result of the positioning of the peak
at the boundary of the SAC and adult classes. It’s clear
that achieving 75 % coverage in SAC and 27.4 % in
adults via annual rounds of treatment has a very consid-
erable impact on the mean intensity of infection in all
age groups. The gradual achievement of this impact can
be compared to the rapid achievement of a similar level
of control after 2 rounds of treatment achieved by Butter-
worth and colleagues in their original study, as recorded
in Fig. 3 [26]. In the latter case, levels of coverage in excess
of 90 % were required across the entire age range of the
population (with the exception of those under 5 years).
Figure 6 plots the time series underlying these calcula-
tions (with parameter values as in Tables 1 and 2), with
treatment coverage extended beyond 2020 at the levels
achieved in 2020. Note that at a level of 75 % coverage
in SAC and 27.4 % coverage in adults the model predicts
that the transmission breakpoint is crossed and trans-
mission is extinguished by 2030.
Sensitivity analyses
We performed a basic sensitivity analysis on the impact
of the treatment coverage trend with respect to some of
the more important or uncertain parameters, the results
of which are summarised in Table 2. Transmission in-
tensity, as captured by R0 in our model, is encapsulates a
large number of features of the transmission cycle and is
likely to vary from community to community. The value
obtained from the current fit (R0 = 1.7) is relatively low
with respect to previous estimates [5, 31]. An increase of
R0 by 1 decreases the impact of treatment by 2020 con-
siderably. However, examination of the time series sug-
gests that elimination is still possible, but delayed
beyond 2030.
The coverage trend shown in Fig. 2 is an average
across many countries in which schistosomiasis is en-
demic. Across individual communities, however, levels
of coverage are likely to vary considerably. Table 2 shows
that the impact of the 2020 level of coverage of children
is relatively small and also linear across all age groups.
This indicates that, even though coverage may vary
across treated communities in a country, average cover-
age levels will give a good estimate of the average effect
on worm burden in the population as a whole.
Coverage of adults is not currently part of the WHO
goals for schistosomiasis, but treatment across the whole
community has also been shown to be highly effective in
the Machakos study [26]. Table 3 shows that treatment
of adults has a relatively small impact on worm burden
reduction overall, with the effect diminishing as coverage
gets higher. This insensitivity reflects the low schisto-
some burden in adults in the data to which we fitted the
model. For other datasets (such as that for Matithini vil-
lage in the same study), a higher burden in adults may
translate to greater sensitivity to adult coverage levels.
Fig. 5 Changes in the mean worm burden in the three age groups and in the overall population mean between 2001 and 2020 with coverage
as defined in Fig. 2. Percentages indicate the worm burden reductions in the respective age groups
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Interrupting transmission
The current ambitions of WHO include the aim of inter-
rupting transmission in defined settings with 75 % cover-
age of SAC and some undefined coverage level in adults
[3]. We examine the feasibility of achieving this aim with
various levels of treatment coverage in pre-SAC, SAC
and adults by plotting an ‘elimination surface’ for treat-
ment coverage required to interrupt transmission. This
is shown in Fig. 7 which records the values of coverage
in pre-SAC, SAC and adults above which, if continued
for 15 years, reduce worm burden to such a level that it
cannot subsequently recover. These ‘breakpoint surfaces’
have been reported in other publications for soil trans-
mitted helminths [6, 7, 32]. This is the first time they
have been calculated for schistosomes. Note that the
predictions are generated under the assumption of mon-
ogamy amongst adult worms. If a degree of polygamy
pertains, the surface will be higher on the SAC axis since
the breakpoint will be more difficult to reach [5, 11].
Much of the shape of the elimination surface can be
understood with reference to the baseline age profile
shown in Fig. 4. For example, egg output from the pre-
SAC age group is -quite low and this corresponds with
the low sensitivity of elimination to coverage in pre-SAC
(the surface is very flat in the direction of changing pre-
SAC coverage). Treatment of pre-SAC is not currently
part of the WHO goals for schistosomiasis. The drug is
not authorised for use in this age group (see Methods
section), although efforts are being made to develop a
suitable formulation [33]. However, our results suggest
that they would be of limited use in bringing about elim-
ination, although they could be important in reducing
morbidity. Coverage of adults is important at low levels,
enabling elimination to be achieved within the WHO
goals for SAC. Further increase in adult coverage has lit-
tle additional effect due to the relatively low worm bur-
dens among adults. The impact of treating adults is
reduced if a longer period of treatment is recovered,
Fig. 6 Predicted time series for mean intensities of infection (epg) in pre-SAC, SAC, adults and overall from 2003 to 2020, with the coverage
trends defined in Fig. 2. After 2020 the coverage is assumed to remain constant at 75 % in Sac and 27.4 % in adults
Table 2 Sensitivity analyses of model projections to changes in the values of key parameters. The numerical values record the
percentage reduction in the predicted mean intensity of infection in each age group from a rising treatment coverage to 75 %, and









Fitted parameter values (Table 1) 73 % 91 % 84 % 86 %
Higher and lower transmission setting (R0 + 1.0, −0.25) 49 %, 81 % 78 %, 94 % 76 %, 86 % 76 %, 90 %
Coverage level achieved in 2020 (60 %, 90 %) 77 %, 67 % 94 %, 85 % 87 %, 79 % 90 %, 81 %
Degree of exposure and contribution of children to the infectious reservoir
(5–16 years) (β2 and β2 + 50 %, −50 %)
73 %, 71 % 91 %, 90 % 84 %, 82 % 87 %, 85 %
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showing that the treating adults reduces the time to elim-
ination rather than the long-term possibility of
elimination.
The close association between the baseline age-profile
and the elimination surface suggests that if the baseline
varies between populations, the conditions under which
elimination can be achieved will vary too. For example,
other age profiles have a stronger presence in worms
within the adult population and this will translate into a
greater sensitivity to adult coverage.
The predictions reported in this paper are for S man-
soni, but given that the life expectancy of S heamato-
bium and its age-profile within the host population are
similar, the predictions should apply for that species too.
In the case of S. japonicum, the added complexity of
multiple zoonotic reservoirs will likely mean that con-
clusions drawn from S. mansoni cannot be directly
transferred to the other species that infest humans.
Model validation
As outlined in the Methods section, validation of model
predictions requires comparison of observed outcomes
with corresponding post-treatment predictions, given
baseline initial conditions and parameter estimates and
data on who is treated, how frequently and who is sur-
veyed. Given the nature of our model, ideal data would
be individual longitudinal egg count data with matching
data on age and treatment history.
Few published epidemiological studies on schisto-
somes have this level of detail, at least in their published
form. The study by Butterworth et al. of S mansoni
transmission and treatment in Machakos district, Kenya
offers a good compromise in that it reports age group-
stratified baseline and re-infection data across several
study arms with data on MDA coverage and timing over
a number of years [24, 26, 34]. We focus on the study
arm in Iietune village. In this population, an initial sur-
vey in 1983 was followed immediately by a round of
MDA. A second round occurred in 1985 and a re-
infection survey was completed in 1987. A coverage of
93 % was achieved in both rounds, assumed for the pur-
pose of validation to be coverage of those eligible for
treatment (5 years or over). We have extracted epg data
from the baseline and the re-infection survey, with the
baseline data being used to parameterize the model
using maximum likelihood techniques.
The results of the validation analysis on the Fulford et
al. data is displayed in Fig. 8. Panel A records the fit of
the model to the observed mean egg counts for S man-
soni in each recorded age group at baseline and also the
comparison between the re-infection data and the
model’s prediction. Note that no revised parameter esti-
mates where made using the reinfection data – so this is
‘true’ validation, in the sense of using the predefined
model to make predictions of MDA impact. It’s clear that
the correspondence with the re-infection data is approxi-
mately correct on average, but there are some discrepan-
cies in the distribution of parasite burden among school-
age children and young adults. Panel B shows the details
of predicted and observed re-infection profile. The model
has successfully captured re-infection levels among older
adults (20+ years), but has overestimated the levels among
individuals in the 10–20 year age bracket. One possible
reason is that the assumption of a single infectious reser-
voir is incorrect. It is possible that young children have a
tendency to form a ‘core re-infection group’. Without this
mechanism, re-infection in this group will be under-
represented by the model relative to the older children,
shifting the infection peak towards older ages. Another
potential reason is immune response to infection and
Table 3 Sensitivity of model projections (percentage reduction in the predicted mean intensity of infection) to changes in the level
of coverage of adults achieved in 2020 (linear trend from last data point in 2013)
Adult coverage by 2020 Pre-SAC mean burden SAC mean burden Adults mean burden Overall population mean burden
15 % 72 90 78 83
30 % 73 91 85 87
45 % 74 92 89 90
60 % 75 92 93 92
75 % 76 93 95 94
Fig. 7 ‘Elimination surface’ for S mansoni calculated for the
parameter assignments listed in Table 1. Levels of coverage above
the surface are predicted to reduce worm burden in the population
within 15 years to such a level that it cannot subsequently recover
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treatment which is not currently captured by the model.
These issues will be explored in future work.
Discussion
The general conclusion generated by the model predic-
tions is that an annual 75 % coverage in SAC and a
modest level of coverage in adults should reduce mean
intensities of infection to very low levels by 2020. In low
to moderate transmission settings continuation of this
coverage for a decade or so should result in transmission
elimination. For high transmission settings, however,
somewhat higher levels of coverage will be required.
These predictions seem to be relatively insensitive to
changes in the parameter estimates explored in Table 2.
The key question, however, is whether coverage can be
raised to 75 % in SAC and modest levels in adults? Con-
comitantly, can drug production levels also be raised to
meet such demands? These questions are beyond the
scope of this paper and the resolution of them lies with
WHO, policy makers, implementers within countries
and the pharmaceutical companies who makes the major
donations of praziquantel.
Model validation against reinfection data indicate that,
while broadly in agreement with the data, there are clear
discrepancies. These arise from two equally important
sources. On the one hand, the failure to capture the be-
haviour of the population in the 12–25 year age range sug-
gests that a more sophisticated model of infectious
contact among children is required. On the other, there is
a lot of missing and uncertain material in the data being
used in this validation, such as past history of treatment
(which we have assumed no past history). The availability
of high quality data is a major issue for model testing and
validation. Far too few published studies record data on
intensity and prevalence by age group (ideally individual
person epg counts) electronically and make such data
freely available to other researchers. This is an important
need in the coming years as MDA coverage is hopefully
increased.
As it currently stands, our model does not include the
effects of immunity. Immune responses are not well
understood, but possible mechanisms include acquired
immunity from past exposure to infection and a long-
lived immune response generated by death of adult worms
[35, 36]. Without a clear understanding of the mecha-
nisms of acquired immunity, it is very hard to disentangle
the effects of immunity from age-dependent exposure to
infection (β). However, re-infection data, stratified by age,
may offer a chance to distinguish the two processes. Our
current model overestimates reinfection in an age-group
that was heavily infected at baseline, perhaps suggesting
that an immune response triggered by treatment may be
responsible. Future work will examine this possibility.
Another potential source of error in our model is the
treatment of host demography. The data used for both
fitting and validation is from studies conducted in the
1980s, but our modelling concerns the past decade and
near future. Within this interval, significant changes in
demography have certainly taken place. We use a
frequency-dependent model of infection whose behav-
iour will not be effected by the absolute host population
(whether absolute population size effects disease dynam-
ics in reality will require detailed analysis of datasets
from different time periods). More significant are
changes in the age distribution of the host population
which will affect the mean force of infection experienced
by individuals and their contributions to the infectious
reservoir. Such effects can be investigated with our
model, but will require high quality infection data from
a range of different demographies.
Broader scientific issues relate to the uncertainties
on biological questions, the quality of data available
for parameter estimation, data on drug coverage levels
and the impact of heterogeneities in transmission.
Fig. 8 Validation of model behaviour against baseline and reinfection data from Iietune village, Machakos district, Kenya. Panel A shows the fitted
equilibrium age profile from the model against baseline data from 1983 and the response of the model in 1987 after two rounds of treatment
(1983, 1985). Panel B shows the details of the model age profile against the re-infection survey data
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Biological uncertainties are key in two areas. The first
is the question of monogamy for adult parasites. The
calculations recorded in this paper will be extended
in future work to look how the assumption of polyg-
amy influences predictions. In rough terms it will
make elimination of transmission a little more diffi-
cult (raising the surface in Fig. 7).
The second biological question relates to the import-
ance of acquired immunity. Again, this requires further
exploration. Previous studies have outline various model
frameworks for helminths to address this issue using in-
fection functions that depend on past exposure to infec-
tion and these will be employed in future analyses.
However, it is possible to speculate on what influence
acquired immunity may have [35]. Broadly speaking, if
immunity is important and builds up through early life
exposure, then repeated MDA will act to reduce herd
immunity in a manner that will increase reinfection rates
after many rounds of treatment as children lack past ex-
perience of infection. This would act to lessen the long
term impact of MDA and require the elimination of
transmission to make sure that, if treatment stopped (or
decreased), the population was not more susceptible to
infection and associated morbidity.
Data availability to test predictions against observa-
tions is good in one context and poor in others. Epi-
demiological data, well stratified by age and sex, on
reinfection post rounds of MDA is good, as well illus-
trated in Fig. 3 by the studies of Butterworth and col-
leagues [17, 26]. Such data facilitates model validation.
Data is poor for the estimation of key population dy-
namic parameters such as density dependent fecundity and
the relationship between epg measures and worm counts
because direct measurements of host worm populations in
vivo is impossible. Estimates can be obtained from experi-
mental animal models (mice and some primate species [37,
38]) as well as from autopsy studies, although these are
very rare and probably constitute a biased sample [39]. The
alternative source for estimates for these parameters is
through fitting complex models to extensive datasets [34].
In this sense, model development and parameterisation for
schistosome species is much more difficult than for soil
transmitted helminths, where many worm expulsion stud-
ies have been published [40–42].
Drug coverage data for praziquantel treatment strati-
fied by the age group treated is poor at present. This
could be easily remedied by requesting countries to rec-
ord this information as treatment coverage expands.
This data is essential for making accurate predictions,
given that for all schistosome species, a significant frac-
tion of the total adult parasite population is harboured
by those over 15 years of age [43].
The transmission of schistosome species relies on hu-
man contact with water, and as such much heterogeneity
exists between endemic settings in the exposure of indi-
viduals by age and gender as a consequence of the prevail-
ing cultural, social and behavioural conditions. Our
predictions were based on parameter values derived from
one medium intensity transmission setting, but in the vil-
lages studied by Fulford et al. in Kenya much variation in
exposure to infection was apparent village by village, relat-
ing to the type of water contact and what sort of aquatic
habitat was present near each village [26]. Addressing
such heterogeneity requires the use of individual based
stochastic models incorporating spatial transmission, and
these will be a priority in future research.
A stochastic framework will also facilitate addressing
other important sources of heterogeneity, such as pre-
disposition to heavy infection [13], and variability in, or
predisposition to, treatment at each round of MDA.
Data requirements in this context include the keeping of
accurate records of precisely who receives treatment at
each round of MDA.
Conclusion
In conclusion, we return to the main prediction of the
model calculations. S. mansoni control, and even the
interruption of transmission, is possible if high levels of
annual treatment coverage in SAC are reached and
maintained, plus some modest coverage in adults of
around 30 %. Reaching the 75 % coverage in SAC in all
endemic regions is the challenge for the coming years.
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